GAIN THERAPEUTICS INC. - COMMON STOCK

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

08 Jan 2025 07:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

07 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

23 Dec 2024 06:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics To Present At Biotech Showcase 2025

11 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

14 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

15 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

07 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at Upcoming Investor Conferences

03 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

30 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

26 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

19 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

29 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

08 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

01 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

09 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

28 Jun 2024 15:39:04 By Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

27 Jun 2024 15:08:08 By Nasdaq GlobeNewswire